Best GLP-1 for Weight Loss in 2026: Ranking Every Option by the Data

Key takeaways:

• Retatrutide (triple agonist) has the highest recorded weight loss at 24.2%, but it is still in clinical trials and NOT available by prescription
• Tirzepatide (Zepbound/Mounjaro) leads among FDA-approved options with 20.9% average weight loss in SURMOUNT-1
• Semaglutide (Wegovy/Ozempic) remains the most widely prescribed and studied at 14.9% average weight loss
• Liraglutide (Saxenda) produces roughly 8% weight loss and is generally considered a second-line option
• Availability and insurance coverage matter as much as raw efficacy -- the best drug is the one you can actually get and afford

Important: This article is for educational and informational purposes only. It is not medical advice. Some compounds discussed are investigational and not yet FDA-approved. Always consult a qualified healthcare provider before starting any weight loss medication. See our full medical disclaimer.

The 2026 GLP-1 landscape

The GLP-1 receptor agonist class has exploded. What started with liraglutide (Saxenda) in 2014 has expanded into a multi-compound arms race between pharmaceutical giants. In 2026, more options exist than ever -- but not all are equally available.

Here is the current state of play, ranked by clinical weight loss data from highest to lowest.

The rankings: weight loss by the numbers

Rank	Compound	Mechanism	Best Weight Loss Data	FDA Status (Weight Loss)
1	Retatrutide	GLP-1 + GIP + Glucagon	24.2% at 48 weeks	Phase 3 trials (NOT approved)
2	Tirzepatide	GLP-1 + GIP	20.9% at 72 weeks	Approved (Zepbound)
3	CagriSema	GLP-1 + Amylin	~22.7% at 68 weeks	Phase 3
4	Semaglutide	GLP-1	14.9% at 68 weeks	Approved (Wegovy)
5	Survodutide	GLP-1 + Glucagon	~18.7% at 46 weeks	Phase 3
6	Orforglipron	GLP-1 (oral, non-peptide)	~14.7% at 36 weeks	Phase 3
7	Liraglutide	GLP-1	~8% at 56 weeks	Approved (Saxenda)

Sources: STEP 1 (PMID: 33567185), SURMOUNT-1 (PMID: 35658024), Retatrutide Phase 2 (PMID: 37351564)

A few critical caveats before we dive deeper. These numbers come from different trials with different populations, durations, and endpoints. Direct comparison across trials is useful for general context but is not scientifically equivalent to a head-to-head study. The SURMOUNT-5 trial, which did compare tirzepatide directly against semaglutide (PMID: 37840095), confirmed that tirzepatide produces greater weight loss.

1. Retatrutide -- the leader with an asterisk

Retatrutide holds the highest weight loss number ever recorded in a controlled obesity trial: 24.2% average body weight loss at 48 weeks, with the weight loss curve still trending downward (PMID: 37351564).

What makes retatrutide different is the third receptor. While tirzepatide targets GLP-1 and GIP, retatrutide adds the glucagon receptor. Glucagon agonism appears to increase energy expenditure and drive liver fat reduction -- an effect not seen as strongly with other GLP-1 class medications.

The asterisk: retatrutide is NOT available. It is in Phase 3 clinical trials (TRIUMPH program) run by Eli Lilly. Approval, if it comes, is likely no earlier than late 2027 or 2028. You cannot currently get retatrutide through any legitimate channel outside of a clinical trial enrollment.

Estimated cost upon approval: unknown, but likely $1,000+ per month based on the pricing of tirzepatide.

2. Tirzepatide -- the best available option

Tirzepatide is the most effective FDA-approved weight loss medication as of 2026.

The SURMOUNT-1 trial showed 20.9% average weight loss at the 15mg dose over 72 weeks (PMID: 35658024). More than half of participants on the highest dose lost over 20% of their body weight. These are results that approach what was previously only achievable through bariatric surgery.

As a dual GLP-1/GIP agonist, tirzepatide pushes two metabolic levers rather than one. The GIP receptor activation appears to enhance the weight loss and metabolic benefits beyond what GLP-1 alone can achieve.

Available as Zepbound (for weight management) and Mounjaro (for type 2 diabetes). Once-weekly subcutaneous injection. Dose titration from 2.5mg to 15mg over several months.

Current cost: approximately $1,060 per month without insurance. Coverage is expanding but still inconsistent.

3. Semaglutide -- the proven standard

Semaglutide remains the most prescribed and most studied GLP-1 for weight loss. The STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks (PMID: 33567185).

While tirzepatide produces greater weight loss in head-to-head comparisons, semaglutide has advantages in other areas. It has been on the market longer, has more long-term safety data, and has broader insurance coverage in many markets. The SELECT trial also demonstrated cardiovascular benefit -- a 20% reduction in major adverse cardiovascular events -- which gives it a unique value proposition for patients with heart disease risk.

Available as Wegovy (for weight management) and Ozempic (for type 2 diabetes). Once-weekly subcutaneous injection. Dose titration from 0.25mg to 2.4mg.

Current cost: approximately $1,300 per month without insurance.

For many patients, semaglutide remains the practical first choice -- not because it produces the most weight loss, but because it is accessible, well-studied, and effective enough to produce clinically meaningful results in the majority of users.

4. The pipeline: what is coming

Several compounds could reshape the rankings by 2027-2028.

Survodutide (detailed profile) is a dual GLP-1/glucagon agonist from Boehringer Ingelheim. Phase 2 data showed approximately 18.7% weight loss at 46 weeks, with particular promise for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH. Phase 3 trials are underway. The glucagon component targets liver fat, making this especially interesting for patients with fatty liver disease.

Orforglipron (detailed profile) is an oral, non-peptide GLP-1 agonist from Eli Lilly. This is significant because it is not a peptide at all -- it is a small molecule that activates the GLP-1 receptor orally without the bioavailability problems of oral semaglutide. Phase 3 data showed approximately 14.7% weight loss at 36 weeks (PMID: 38587993). If approved, it could make GLP-1 therapy accessible to the massive population of people who will not inject themselves.

CagriSema combines semaglutide with cagrilintide (an amylin analog) in a single injection. Novo Nordisk's strategy is to layer amylin-mediated satiety on top of GLP-1 appetite suppression. Phase 3 data showed approximately 22.7% weight loss. This would keep Novo Nordisk competitive against Eli Lilly's tirzepatide and retatrutide.

Mazdutide (detailed profile) is a dual GLP-1/glucagon agonist developed by Innovent Biologics, primarily targeting the Chinese market. Phase 3 data showed competitive weight loss results. Its relevance to the US market depends on future regulatory filings.

Decision framework: how to choose

Raw weight loss percentages are one factor. Here is what else matters.

If maximum weight loss is the priority and you have access: Tirzepatide (Zepbound) at the 15mg dose is currently the most effective available option.

If your provider recommends starting with a GLP-1 and cost or access drives the decision: Semaglutide (Wegovy) has broader coverage and a longer track record. Many clinicians start patients here.

If you have cardiovascular risk factors: Semaglutide has the SELECT trial data showing cardiovascular benefit. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing.

If you cannot tolerate GI side effects: Switching between compounds sometimes helps. Tirzepatide has shown lower GI side effect rates than semaglutide in head-to-head data despite greater weight loss. Some patients who cannot tolerate one can tolerate the other.

If needle aversion is a barrier: Watch for orforglipron. If approved, it would be the first oral non-peptide GLP-1 that bypasses the bioavailability limitations of oral semaglutide.

If you have fatty liver concerns: Retatrutide and survodutide both show promise for liver fat reduction due to glucagon receptor activity. Retatrutide is only available in clinical trials. Survodutide is advancing through Phase 3 for MASH.

If cost is the primary barrier: Compounded semaglutide has been available at lower cost points, though regulatory changes continue to affect this market. Liraglutide (Saxenda) is less effective but sometimes available at lower cost.

What this means going forward

The GLP-1 class is moving toward multi-receptor agonism as the standard. Single-receptor GLP-1s like semaglutide and liraglutide are effective, but dual and triple agonists consistently produce greater metabolic improvement.

By 2028, the landscape will likely include at least 2-3 additional approved options, oral alternatives that work as well as injectables, and combination therapies that target multiple metabolic pathways.

But the best GLP-1 for weight loss in 2026 is not necessarily the one with the highest number in a clinical trial. It is the one that your provider recommends for your specific situation, that you can access and afford, and that you can tolerate well enough to stay on long-term.

For deeper comparisons between the two current leaders, read our complete semaglutide vs tirzepatide analysis. For the latest on the most anticipated pipeline compound, see our retatrutide results breakdown.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PMID: 37351564
4. Wharton S, et al. Tirzepatide vs Semaglutide for Weight Loss (SURMOUNT-5). PMID: 37840095
5. Frias JP, et al. Orforglipron Phase 3 Results. PMID: 38587993

---

This article is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. See our full medical disclaimer.